179 results on '"Birkett, Donald J."'
Search Results
2. New Uses for Allopurinol
3. Development of an Australian Drug Utilisation Database: A Report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee
4. The xenobiotic inhibitor profile of cytochrome P4502C8
5. [14] Assays of omeprazole metabolism as a substrate probe for human CYP isoforms
6. [15] Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
7. Nonspecific binding of drugs to human liver microsomes
8. Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism
9. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia
10. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
11. Interfering ribonucleic acids that suppress expression of multiple unrelated genes
12. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo
13. Serum Alkaline Phosphatase In Pregnancy: An Immunological Study
14. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate sensitivity and regioselectivity
15. Access to medicines and high-quality therapeutics: Global responsibilities for clinical pharmacology
16. Biochemical validation of self-reported caffeine consumption during caffeine fading
17. Protein Binding of some Non-steroidal Anti-inflammatory Drugs in Rheumatoid Arthritis
18. Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes
19. Changes to the Pharmaceutical Benefits Advisory Committee
20. Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database
21. Interfering ribonucleic acids that suppress expression of multiple unrelated genes
22. The DNAzymes Rs6, Dz13, and DzF Have Potent Biologic Effects Independent of Catalytic Activity
23. Generics - equal or not?
24. A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia
25. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia
26. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
27. Recent changes in the profile of prescription NSAID use in Australia
28. Prescription use by patients with concession cards
29. Allelic and functional variability of cytochrome P4502C9
30. The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
31. Pattern of non‐steroidal anti‐inflammatory drug use in Australia 1990–1994 A report from the Drug Utilization Sub‐Committee of the Pharmaceutical Benefits Advisory Committee
32. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen
33. The use of caffeine as a metabolic probe for human drug metabolizing enzymes
34. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2
35. Caffeine metabolism by human hepatic cytochromes p450: Contributions of 1A2, 2E1 and 3A isoforms
36. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques
37. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
38. High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism
39. High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes
40. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects
41. The misuse of urinary metabolite excretion data in drug metabolism studies
42. Caffeine as a probe for human cytochromes P450
43. The Flinders experiment in medical education revisited
44. Profiles of antibacterial drug use in Australia and trends from 1987 to 1989: A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee
45. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
46. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
47. The xenobiotic inhibitor profile of cytochrome P4502C8.
48. Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database.
49. Effects of time of dose in relation to food on the bioavailability of Theo-Dur Sprinkle at steady state in asthmatic children.
50. Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.